GEN | News Highlights:Partnership Established to Develop VLP Malaria Vaccine in IndiaPosted: July 16, 2012
The initiative is being funded by India’s Department of Biotechnology Vaccine Grand Challenge Program, and will be managed by the Malaria Vaccine Development Program, a nonprofit organization based in New Delhi that supports the development of malaria vaccines. CPL Biologicals is a joint-venture biotech firm established by Novavax and India’s Cadila Pharmaceuticals.
Under terms of the agreement, the collaborators will initially develop and evaluate VLPs that express the Plasmodium falciparum circumsporozoite protein (PfCSP), which they point out forms the basis of the only recombinant malaria vaccine that has shown efficacy in field trials to date. Once feasibility of the Novavax technology has been demonstrated, the partners will work to generate VLPs against other antigens from other stages of malaria parasites. They suggest that a multi-stage VLP vaccine could provide higher efficacy than those based on a single antigen or that target just one stage of the parasite’s life cycle. CPLB will be responsible for the manufacture of constructs for advanced preclinical studies, clinical trials, and commercial supply.